AUTL
NASDAQAutolus Therapeutics plc
News · 26 weeks43-25%
2026-04-192026-10-11
Mix1590d
- SEC Filings7(47%)
- Other5(33%)
- Earnings2(13%)
- Insider1(7%)
Latest news
25 items- PRAutolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026LONDON and GAITHERSBURG, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced the online publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2026 meeting being held November 6-11, 2026 in Orlando, Florida. Updated data from the ongoing Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) will be presented in a poster on November 10. Abstract: 2216Title: Obecabtagene autoleucel (obe-cel), a CD19-targeting Chimeric Antigen
- SECSEC Form EFFECT filed by Autolus Therapeutics plcEFFECT - Autolus Therapeutics plc (0001730463) (Filer)
- SECSEC Form 424B3 filed by Autolus Therapeutics plc424B3 - Autolus Therapeutics plc (0001730463) (Filer)
- SECSEC Form DEL AM filed by Autolus Therapeutics plcDEL AM - Autolus Therapeutics plc (0001730463) (Filer)
- SECSEC Form S-3 filed by Autolus Therapeutics plcS-3 - Autolus Therapeutics plc (0001730463) (Filer)
- PRAutolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus NephritisLONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to obecabtagene autoleucel (obe-cel) for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN). RMAT designation is a program created under the 21st Century Cures Act to accelerate the development and regulatory review of regenerative medicine therapies, including cell therapies, intende
- INSIDERU.S. CCO & Country Gen Manager Piccina Cintia sold $15,682 worth of American Depositary Shares (6,713 units at $2.34) and exercised 20,000 units of American Depositary Shares at a strike of $2.35 (SEC Form 4)4 - Autolus Therapeutics plc (0001730463) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Autolus Therapeutics plcSCHEDULE 13G/A - Autolus Therapeutics plc (0001730463) (Subject)
- SECSEC Form 10-Q filed by Autolus Therapeutics plc10-Q - Autolus Therapeutics plc (0001730463) (Filer)
- SECAutolus Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Autolus Therapeutics plc (0001730463) (Filer)
- PRAutolus Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesCompany reports AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $45.7 million in Q2 2026, an increase of 119% year-over-yearFY 2026 net product revenue guidance increased to $140 - $150 millionGross margin increased in Q2 2026 , driven by growing volumes and cost reduction initiatives Capital base strengthened through five-year, interest-only credit facility of up to $250 Million with Perceptive Advisors with $75 million funded at closeObe-cel clinical development programs on track with trial enrollment ongoing in lupus nephritis, pediatric ALL and progressive multiple sclerosis (MS)Conference call to be held today at 8:30am EDT/1:30pm BST: conference call participants sh
- PRAutolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its second quarter 2026 financial results and operational highlights before open of U.S. markets on Tuesday, August 11, 2026. Management will host a conference call and webcast at 8:30am EDT / 1:30pm BST to discuss the Company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are requ
- SECAutolus Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Autolus Therapeutics plc (0001730463) (Filer)
- PRAutolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive AdvisorsCompany reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 – $150 million, from $120 – $135 millionCapital base strengthened through five-year, interest-only credit facility with $75 million funded at closeAutolus to report Q2 2026 financial results on August 11, 2026 LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced preliminary second quarter 2026 AUC
- SECAutolus Therapeutics plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - Autolus Therapeutics plc (0001730463) (Filer)
- INSIDERSEC Form 4 filed by Director Young William D4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Rao Madduri Ravin4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Richardson Ryan4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Leiderman Elisabeth4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Iannone Robert4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Butitta Cynthia M4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Bain Linda4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Azelby Robert4 - Autolus Therapeutics plc (0001730463) (Issuer)
- INSIDERSEC Form 4 filed by Director Bonney Michael W4 - Autolus Therapeutics plc (0001730463) (Issuer)
- PRAutolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)LONDON & GAITHERSBURG, Md., July 01, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 25,420 American Depositary Shares and 87,530 restricted stock units (RSUs), each representing an equal number of ordinary shares, to 13 employees pursuant to the Company’s 2025 Inducement Plan. The stock options and RSUs were granted as an inducement material to the individual becoming an employee of Autolus
AUTL FAQ
7 questionsWhat does Autolus Therapeutics plc do?
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is...Where does AUTL stock trade?
Autolus Therapeutics plc (AUTL) is listed on NASDAQ.What sector and industry is AUTL in?
Autolus Therapeutics plc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Autolus Therapeutics plc go public?
Autolus Therapeutics plc (AUTL) completed its IPO in 2018.What are analysts saying about AUTL?
Autolus Therapeutics plc has had 6 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $900.00 price target on 2026-02-17. Recent price targets range from $500.00 to $1300.00.What companies are similar to AUTL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare AUTL side-by-side with any of them on Quantisnow.How can I track AUTL on Quantisnow?
Quantisnow aggregates Autolus Therapeutics plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AUTL to receive live email and push alerts on every new disclosure.